Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 959

1.

Allogeneic hematopoietic cell transplantation in patients with untreated acute myeloid leukemia: a KSGCT multicenter retrospective analysis.

Tachibana T, Ishizaki T, Takahashi S, Najima Y, Kimura SI, Sakaida E, Onizuka M, Mori T, Fujisawa S, Fujiwara SI, Saito T, Hagihara M, Aotsuka N, Gotoh M, Usuki K, Tsukada N, Kanda J, Kanamori H, Kanda Y, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT).

Bone Marrow Transplant. 2019 Sep 19. doi: 10.1038/s41409-019-0689-8. [Epub ahead of print] No abstract available.

PMID:
31537900
2.

A Prospective, Longitudinal Observation of the Incidence, Treatment, and Survival of Late Acute and Chronic Graft-versus-host disease by National Institutes of Health Criteria in a Japanese cohort.

Ohwada C, Sakaida E, Igarashi A, Kobayashi T, Doki N, Mori T, Kato J, Koda Y, Kanamori H, Tanaka M, Tachibana T, Fujisawa S, Nakajima Y, Numata A, Toyosaki M, Aoyama Y, Onizuka M, Hagihara M, Koyama S, Kanda Y, Nakasone H, Shimizu H, Kato S, Watanabe R, Shono K, Sakai R, Saito T, Nakaseko C, Okamoto S.

Biol Blood Marrow Transplant. 2019 Sep 16. pii: S1083-8791(19)30627-5. doi: 10.1016/j.bbmt.2019.09.016. [Epub ahead of print]

PMID:
31536824
3.

A critical role of VMP1 in lipoprotein secretion.

Morishita H, Zhao YG, Tamura N, Nishimura T, Kanda Y, Sakamaki Y, Okazaki M, Li D, Mizushima N.

Elife. 2019 Sep 17;8. pii: e48834. doi: 10.7554/eLife.48834.

4.

Alloreactive T Cells Display a Distinct Chemokine Profile in Response to Conditioning in Xenogeneic GVHD Models.

Kawasaki Y, Sato K, Nakano H, Hayakawa H, Izawa J, Takayama N, Mashima K, Oh I, Minakata D, Yamasaki R, Morita K, Ashizawa M, Yamamoto C, Hatano K, Fujiwara SI, Ohmine K, Muroi K, Ito R, Hayakawa M, Ohmori T, Kanda Y.

Transplantation. 2019 Sep;103(9):1834-1843. doi: 10.1097/TP.0000000000002756.

PMID:
31461746
5.

Comparison of Danaparoid Sodium and Synthetic Protease Inhibitors for the Treatment of Disseminated Intravascular Coagulation Associated with Hematological Malignancies: A Retrospective Analysis.

Minakata D, Fujiwara SI, Hayakawa J, Nakasone H, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Ochi SI, Nagayama T, Mashima K, Umino K, Nakano H, Yamasaki R, Morita K, Kawasaki Y, Sugimoto M, Ishihara Y, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Ohmori T, Kanda Y.

Acta Haematol. 2019 Aug 28:1-10. doi: 10.1159/000501818. [Epub ahead of print]

PMID:
31461700
6.

Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms.

Guth BD, Engwall M, Eldridge S, Foley CM, Guo L, Gintant G, Koerner J, Parish ST, Pierson JB, Ribeiro AJS, Zabka T, Chaudhary KW, Kanda Y, Berridge B.

Front Pharmacol. 2019 Aug 9;10:884. doi: 10.3389/fphar.2019.00884. eCollection 2019. Review.

7.

Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia.

Sakaguchi M, Yamaguchi H, Kuboyama M, Najima Y, Usuki K, Ueki T, Oh I, Mori S, Kawata E, Uoshima N, Kobayashi Y, Kako S, Tajika K, Shono K, Kayamori K, Hagihara M, Kanda J, Uchiyama H, Kuroda J, Uchida N, Kubota Y, Kimura S, Kurosawa S, Date K, Nakajima N, Marumo A, Omori I, Fujiwara Y, Terada K, Yui S, Wakita S, Arai K, Kitano T, Kakihana K, Kanda Y, Ohashi K, Fukuda T, Inokuchi K.

Int J Hematol. 2019 Aug 20. doi: 10.1007/s12185-019-02720-z. [Epub ahead of print]

PMID:
31432396
8.

Comprehensive analysis of syndromic hearing loss patients in Japan.

Ideura M, Nishio SY, Moteki H, Takumi Y, Miyagawa M, Sato T, Kobayashi Y, Ohyama K, Oda K, Matsui T, Ito T, Suzumura H, Nagai K, Izumi S, Nishiyama N, Komori M, Kumakawa K, Takeda H, Kishimoto Y, Iwasaki S, Furutate S, Ishikawa K, Fujioka M, Nakanishi H, Nakayama J, Horie R, Ohta Y, Naito Y, Kakudo M, Sakaguchi H, Kataoka Y, Sugahara K, Hato N, Nakagawa T, Tsuchihashi N, Kanda Y, Kihara C, Tono T, Miyanohara I, Ganaha A, Usami SI.

Sci Rep. 2019 Aug 19;9(1):11976. doi: 10.1038/s41598-019-47141-4.

9.

Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.

Akahoshi Y, Nishiwaki S, Mizuta S, Ohashi K, Uchida N, Tanaka M, Fukuda T, Ozawa Y, Takahashi S, Onizuka M, Shiratori S, Nakamae H, Kanda Y, Ichinohe T, Atsuta Y, Kako S; Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Cancer Sci. 2019 Aug 11. doi: 10.1111/cas.14167. [Epub ahead of print]

10.

Impact of High-Frequency HLA Haplotypes on Clinical Cytomegalovirus Reactivation in Allogeneic Hematopoietic Stem Cell Transplantation.

Kawase T, Tanaka H, Kojima H, Uchida N, Ohashi K, Fukuda T, Ozawa Y, Ikegame K, Eto T, Mori T, Miyamoto T, Hidaka M, Shiratori S, Takanashi M, Atsuta Y, Ichinohe T, Kanda Y, Kanda J; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant. 2019 Aug 7. pii: S1083-8791(19)30514-2. doi: 10.1016/j.bbmt.2019.07.042. [Epub ahead of print]

PMID:
31400501
11.

Retinoic acid promotes barrier functions in human iPSC-derived intestinal epithelial monolayers.

Yamada S, Kanda Y.

J Pharmacol Sci. 2019 Jul 26. pii: S1347-8613(19)35687-7. doi: 10.1016/j.jphs.2019.06.012. [Epub ahead of print]

12.

Updated Clinical Outcomes of Hematopoietic Stem Cell Transplantation Using Myeloablative Total Body Irradiation with Ovarian Shielding to Preserve Fertility.

Ashizawa M, Akahoshi Y, Nakano H, Kawamura S, Takeshita J, Yoshino N, Misaki Y, Yoshimura K, Gomyo A, Tamaki M, Kusuda M, Kameda K, Wada H, Kawamura K, Sato M, Terasako-Saito K, Tanihara A, Kimura SI, Nakasone H, Kako S, Akahane K, Wakatsuki M, Shirai K, Kanda Y.

Biol Blood Marrow Transplant. 2019 Aug 5. pii: S1083-8791(19)30511-7. doi: 10.1016/j.bbmt.2019.07.039. [Epub ahead of print]

PMID:
31394267
13.

Analysis of electro-mechanical relationship in human iPS cell-derived cardiomyocytes sheets under proarrhythmic condition assessed by simultaneous field potential and motion vector recordings.

Sugiyama A, Hagiwara-Nagasawa M, Kambayashi R, Goto A, Chiba K, Naito AT, Kanda Y, Matsumoto A, Izumi-Nakaseko H.

J Pharmacol Sci. 2019 Jul 19. pii: S1347-8613(19)35682-8. doi: 10.1016/j.jphs.2019.07.006. [Epub ahead of print]

14.

Bacteroides in colonic mucosa-associated microbiota affects the development of minimal hepatic encephalopathy in patients with cirrhosis.

Haraguchi M, Miuma S, Masumoto H, Ichikawa T, Kanda Y, Sasaki R, Fukushima M, Miyaaki H, Taura N, Nakao K.

Hepatol Int. 2019 Jul;13(4):482-489. doi: 10.1007/s12072-019-09963-2. Epub 2019 Jul 9.

PMID:
31290070
15.

Dasatinib can Impair Left Ventricular Mechanical Function But May Lack Proarrhythmic Effect: A Proposal of Non-clinical Guidance for Predicting Clinical Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors.

Izumi-Nakaseko H, Fujiyoshi M, Hagiwara-Nagasawa M, Goto A, Chiba K, Kambayashi R, Naito AT, Ando K, Kanda Y, Ishii I, Sugiyama A.

Cardiovasc Toxicol. 2019 Jul 6. doi: 10.1007/s12012-019-09538-5. [Epub ahead of print]

PMID:
31280457
16.

Systematic expression analysis of genes related to generation of action potentials in human iPS cell-derived cardiomyocytes.

Kodama M, Furutani K, Kimura R, Ando T, Sakamoto K, Nagamori S, Ashihara T, Kurachi Y, Sekino Y, Furukawa T, Kanda Y, Kurokawa J.

J Pharmacol Sci. 2019 Jun 21. pii: S1347-8613(19)34171-4. doi: 10.1016/j.jphs.2019.06.006. [Epub ahead of print]

17.

Cardiotoxicity assessment of drugs using human iPS cell-derived cardiomyocytes: From proarrhythmia risk to cardiooncology.

Satsuka A, Kanda Y.

Curr Pharm Biotechnol. 2019 Jun 28. doi: 10.2174/1389201020666190628143345. [Epub ahead of print]

PMID:
31264543
18.

Predictive value of soluble interlukin-2 receptor level at diagnosis on the outcome for patients with classical Hodgkin lymphoma treated with ABVD with or without radiotherapy.

Umino K, Fujiwara SI, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Ochi SI, Nagayama T, Mashima K, Minakata D, Nakano H, Yamasaki R, Morita K, Kawasaki Y, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y.

Ann Hematol. 2019 Sep;98(9):2121-2129. doi: 10.1007/s00277-019-03738-3. Epub 2019 Jun 25.

PMID:
31240469
19.

Depolysulfidation of Drp1 induced by low-dose methylmercury exposure increases cardiac vulnerability to hemodynamic overload.

Nishimura A, Shimoda K, Tanaka T, Toyama T, Nishiyama K, Shinkai Y, Numaga-Tomita T, Yamazaki D, Kanda Y, Akaike T, Kumagai Y, Nishida M.

Sci Signal. 2019 Jun 25;12(587). pii: eaaw1920. doi: 10.1126/scisignal.aaw1920.

PMID:
31239323
20.

Chemical modification-mediated optimisation of bronchodilatory activity of mepenzolate, a muscarinic receptor antagonist with anti-inflammatory activity.

Yamashita Y, Tanaka KI, Yamakawa N, Asano T, Kanda Y, Takafuji A, Kawahara M, Takenaga M, Fukunishi Y, Mizushima T.

Bioorg Med Chem. 2019 Aug 1;27(15):3339-3346. doi: 10.1016/j.bmc.2019.06.016. Epub 2019 Jun 8.

PMID:
31204225
21.

Prognostic impact of cytogenetic abnormalities in adult patients with Philadelphia chromosome-negative ALL who underwent an allogeneic transplant.

Shimizu H, Doki N, Kanamori H, Sakura T, Mori T, Machida S, Takahashi S, Ohwada C, Fujisawa S, Yano S, Hagihara M, Kanda Y, Onoda M, Gotoh M, Kako S, Taguchi J, Usuki K, Kawai N, Aotsuka N, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT).

Bone Marrow Transplant. 2019 Jun 11. doi: 10.1038/s41409-019-0585-2. [Epub ahead of print]

PMID:
31186516
22.

Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis.

Tachibana T, Kanda J, Ishizaki T, Najima Y, Tanaka M, Doki N, Fujiwara SI, Kimura SI, Onizuka M, Takahashi S, Saito T, Mori T, Fujisawa S, Sakaida E, Matsumoto K, Aotsuka N, Goto M, Watanabe R, Shono K, Usuki K, Tsukada N, Kanamori H, Kanda Y, Okamoto S; Kanto Study; Group for Cell Therapy (KSGCT).

Leukemia. 2019 May 30. doi: 10.1038/s41375-019-0494-9. [Epub ahead of print]

PMID:
31147621
23.

Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement.

McCune JS, Quinones CM, Ritchie J, Carpenter PA, van Maarseveen E, Yeh RF, Anasetti C, Boelens JJ, Hamerschlak N, Hassan M, Kang HJ, Kanda Y, Paci A, Perales MA, Shaw PJ, Seewaldt VL, Savani BN, Hsieh A, Poon B, Mohty M, Pulsipher MA, Pasquini M, Dupuis LL.

Biol Blood Marrow Transplant. 2019 May 25. pii: S1083-8791(19)30332-5. doi: 10.1016/j.bbmt.2019.05.021. [Epub ahead of print]

PMID:
31136799
24.

Resolved versus Active Chronic Graft-versus-Host Disease: Impact on Post-Transplantation Quality of Life.

Kurosawa S, Yamaguchi T, Oshima K, Yanagisawa A, Fukuda T, Kanamori H, Mori T, Takahashi S, Kondo T, Kohno A, Miyamura K, Umemoto Y, Teshima T, Taniguchi S, Yamashita T, Inamoto Y, Kanda Y, Okamoto S, Atsuta Y.

Biol Blood Marrow Transplant. 2019 May 24. pii: S1083-8791(19)30327-1. doi: 10.1016/j.bbmt.2019.05.016. [Epub ahead of print]

PMID:
31129353
25.

OTOF mutation analysis with massively parallel DNA sequencing in 2,265 Japanese sensorineural hearing loss patients.

Iwasa YI, Nishio SY, Sugaya A, Kataoka Y, Kanda Y, Taniguchi M, Nagai K, Naito Y, Ikezono T, Horie R, Sakurai Y, Matsuoka R, Takeda H, Abe S, Kihara C, Ishino T, Morita SY, Iwasaki S, Takahashi M, Ito T, Arai Y, Usami SI.

PLoS One. 2019 May 16;14(5):e0215932. doi: 10.1371/journal.pone.0215932. eCollection 2019.

26.

A consideration for efficient unrelated hematopoietic stem cell source acquisition-from an experience of Japan.

Nishiwaki S, Miyamura K, Kanda Y, Takanashi M, Uchida N, Fukuda T, Ikegame K, Ohashi K, Eto T, Ozawa Y, Shiratori S, Iwato K, Matsuoka KI, Hidaka M, Ichinohe T, Atsuta Y, Kodera Y, Okamoto S.

Bone Marrow Transplant. 2019 May 14. doi: 10.1038/s41409-019-0542-0. [Epub ahead of print] No abstract available.

PMID:
31089273
27.

Unit selection for umbilical cord blood transplantation for adults with acute myeloid leukemia in complete remission: a Japanese experience.

Yanada M, Konuma T, Kuwatsuka Y, Kondo T, Kawata T, Takahashi S, Uchida N, Miyakoshi S, Tanaka M, Ozawa Y, Sawa M, Nakamae H, Aotsuka N, Kanda J, Takanashi M, Kanda Y, Atsuta Y, Yano S.

Bone Marrow Transplant. 2019 May 8. doi: 10.1038/s41409-019-0539-8. [Epub ahead of print]

PMID:
31068659
28.

Better disease control before allogeneic stem cell transplantation is crucial to improve the outcomes of transplantation for acute myeloid leukemia patients with extramedullary disease.

Yamasaki S, Aoki J, Mori J, Mizuno S, Uchida N, Ohashi K, Fukuda T, Ikegame K, Eto T, Ogawa Y, Tanaka M, Hidaka M, Iwato K, Sawa M, Ichinohe T, Kanda Y, Atsuta Y, Yanada M, Yano S; Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Bone Marrow Transplant. 2019 Apr 10. doi: 10.1038/s41409-019-0527-z. [Epub ahead of print] No abstract available.

PMID:
30971777
29.

Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with hepatitis-associated aplastic anemia.

Mori T, Onishi Y, Ozawa Y, Kato C, Kai T, Kanda Y, Kurokawa M, Tanaka M, Ashida T, Sawayama Y, Fukuda T, Ichinohe T, Atsuta Y, Yamazaki H.

Int J Hematol. 2019 Jun;109(6):711-717. doi: 10.1007/s12185-019-02644-8. Epub 2019 Apr 8.

PMID:
30963471
30.

Impact of the soluble interleukin-2 receptor level in the relapsed or refractory phase on the clinical outcome of patients with diffuse large B-cell lymphoma.

Umino K, Fujiwara SI, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Ochi SI, Nagayama T, Mashima K, Minakata D, Nakano H, Yamasaki R, Morita K, Kawasaki Y, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y.

Leuk Lymphoma. 2019 Aug;60(8):1926-1933. doi: 10.1080/10428194.2018.1564824. Epub 2019 Apr 5.

PMID:
30947577
31.

Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome.

Shimomura Y, Hara M, Tachibana T, Ohashi K, Sakura T, Fukuda T, Nakazawa H, Iwato K, Kanda Y, Ikeda T, Eto T, Kanda J, Ichinohe T, Atsuta Y, Ishikawa T, Ishiyama K.

Br J Haematol. 2019 Jul;186(1):86-90. doi: 10.1111/bjh.15898. Epub 2019 Apr 2.

PMID:
30941758
32.

Cryoprotectant-free cryopreservation of mammalian cells by superflash freezing.

Akiyama Y, Shinose M, Watanabe H, Yamada S, Kanda Y.

Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7738-7743. doi: 10.1073/pnas.1808645116. Epub 2019 Apr 1.

PMID:
30936320
33.

Multiple myeloma derived from a kidney transplant donor who also developed myeloma after kidney donation.

Fujiwara SI, Ikeda T, Morita K, Shinzato T, Ishikawa N, Nakamura N, Yagisawa T, Kanda Y.

Am J Transplant. 2019 Aug;19(8):2374-2377. doi: 10.1111/ajt.15373. Epub 2019 Apr 19.

PMID:
30916888
34.

Short-term clinical outcomes after HLA 1-locus mismatched uPBSCT are similar to that after HLA-matched uPBSCT and uBMT.

Fuji S, Miyamura K, Kanda Y, Fukuda T, Kobayashi T, Ozawa Y, Iwato K, Uchida N, Eto T, Ashida T, Mori T, Sawa M, Ichinohe T, Atsuta Y, Kanda J; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Int J Hematol. 2019 Jun;109(6):684-693. doi: 10.1007/s12185-019-02631-z. Epub 2019 Mar 15.

PMID:
30877606
35.

ABO blood type incompatibility lost the unfavorable impact on outcome in unrelated bone marrow transplantation.

Kimura F, Kanda J, Ishiyama K, Yabe T, Yoshifuji K, Fukuda T, Ozawa Y, Iwato K, Eto T, Mori T, Uchida N, Ota S, Sakura T, Ichinohe T, Atsuta Y, Kanda Y; donor/source working group of the Japan Society for Hematopoietic Cell Transplantation.

Bone Marrow Transplant. 2019 Mar 13. doi: 10.1038/s41409-019-0496-2. [Epub ahead of print]

PMID:
30867557
36.

Comparison of Outcomes of Allogeneic Transplantation for Primary Myelofibrosis among Hematopoietic Stem Cell Source Groups.

Murata M, Takenaka K, Uchida N, Ozawa Y, Ohashi K, Kim SW, Ikegame K, Kanda Y, Kobayashi H, Ishikawa J, Ago H, Hirokawa M, Fukuda T, Atsuta Y, Kondo T.

Biol Blood Marrow Transplant. 2019 Aug;25(8):1536-1543. doi: 10.1016/j.bbmt.2019.02.019. Epub 2019 Mar 1.

PMID:
30826464
37.

TAFRO Syndrome with an Anterior Mediastinal Mass and Lethal Autoantibody-Mediated Thrombocytopenia: An Autopsy Case Report.

Morita K, Fujiwara SI, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Ochi SI, Nagayama T, Mashima K, Umino K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Yamamoto C, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Ashizawa K, Yamamoto Y, Oshiro H, Kanda Y.

Acta Haematol. 2019;141(3):158-163. doi: 10.1159/000492743. Epub 2019 Feb 20.

PMID:
30799408
38.

Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation.

Fujimoto A, Hiramoto N, Yamasaki S, Inamoto Y, Uchida N, Maeda T, Mori T, Kanda Y, Kondo T, Shiratori S, Miyakoshi S, Ishiyama K, Ikegame K, Matsuhashi Y, Tanaka J, Ichinohe T, Atsuta Y, Ogata M, Suzuki R.

Biol Blood Marrow Transplant. 2019 Jul;25(7):1441-1449. doi: 10.1016/j.bbmt.2019.02.016. Epub 2019 Feb 20.

PMID:
30794929
39.

Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents.

Mizuno S, Kawamura K, Hanamura I, Sunami K, Mori T, Nakamura F, Iida S, Nakazawa H, Makita M, Kako S, Sawa M, Ueda Y, Takahashi H, Kanda Y, Ichinohe T, Atsuta Y, Takamatsu H, Takami A.

Bone Marrow Transplant. 2019 Feb 19. doi: 10.1038/s41409-019-0478-4. [Epub ahead of print]

PMID:
30783208
40.

Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds.

Tobinaga H, Kameyama T, Asahi K, Horiguchi T, Oohara M, Tada Y, Fuchino K, Jikihara S, Endoh T, Kurihara N, Kanda Y, Ogawa M, Tamura N, Yagi S, Taniguchi E, Takahara Y, Shimada S, Takeyama C, Yamamoto S, Shinohara S, Kai H.

Bioorg Med Chem Lett. 2019 Mar 1;29(5):688-693. doi: 10.1016/j.bmcl.2019.01.039. Epub 2019 Feb 1.

PMID:
30728111
41.

Pharmacological inhibition of mTORC1 but not mTORC2 protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism through Akt and autophagy induction.

Kakiuchi Y, Yurube T, Kakutani K, Takada T, Ito M, Takeoka Y, Kanda Y, Miyazaki S, Kuroda R, Nishida K.

Osteoarthritis Cartilage. 2019 Jun;27(6):965-976. doi: 10.1016/j.joca.2019.01.009. Epub 2019 Feb 1.

42.

Measurement of J-Tpeakc along with QT-Interval Prolongation May Increase the Assay Sensitivity and Specificity for Predicting the Onset of Drug-Induced Torsade de Pointes: Experimental Evidences Based on Proarrhythmia Model Animals.

Goto A, Hagiwara-Nagasawa M, Kambayashi R, Chiba K, Izumi-Nakaseko H, Naito AT, Kanda Y, Sugiyama A.

Cardiovasc Toxicol. 2019 Aug;19(4):357-364. doi: 10.1007/s12012-019-09506-z.

PMID:
30712162
43.

Effect of Differences in Axial Thickness and Type of Cement on Fracture Resistance in Composite Resin CAD/CAM Crowns.

Masuda T, Nomoto S, Sato T, Kanda Y, Sakai T, Tsuyuki Y.

Bull Tokyo Dent Coll. 2019 Feb 28;60(1):17-27. doi: 10.2209/tdcpublication.2018-0022. Epub 2019 Jan 31.

44.

Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index.

Kawasaki Y, Kimura SI, Nakano H, Mashima K, Shirato Y, Kawaguchi SI, Toda Y, Ochi SI, Nagayama T, Minakata D, Yamasaki R, Morita K, Ashizawa M, Yamamoto C, Hatano K, Sato K, Oh I, Fujiwara SI, Ohmine K, Kako S, Muroi K, Kanda Y.

Int J Hematol. 2019 Apr;109(4):470-476. doi: 10.1007/s12185-019-02593-2. Epub 2019 Jan 25.

PMID:
30684252
45.

Clinical significance of low-dose total body irradiation in HLA-mismatched reduced-intensity stem cell transplantation.

Fujiwara SI, Kanda J, Tatara R, Ogawa H, Fukuda T, Okumura H, Ohashi K, Iwato K, Ueda Y, Ishiyama K, Eto T, Matsuoka KI, Nakamae H, Onizuka M, Atsuta Y, Kanda Y; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Bone Marrow Transplant. 2019 Aug;54(8):1327-1336. doi: 10.1038/s41409-019-0434-3. Epub 2019 Jan 22.

PMID:
30670824
46.

11-Step Total Synthesis of Teleocidins B-1-B-4.

Nakamura H, Yasui K, Kanda Y, Baran PS.

J Am Chem Soc. 2019 Jan 30;141(4):1494-1497. doi: 10.1021/jacs.8b13697. Epub 2019 Jan 15.

PMID:
30636411
47.

Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors.

Wakamatsu M, Terakura S, Ohashi K, Fukuda T, Ozawa Y, Kanamori H, Sawa M, Uchida N, Ota S, Matsushita A, Kanda Y, Nakamae H, Ichinohe T, Kato K, Murata M, Atsuta Y, Teshima T; GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Blood Adv. 2019 Jan 22;3(2):105-115. doi: 10.1182/bloodadvances.2018025643.

48.

Haploidentical transplantation using low-dose alemtuzumab: Comparison with haploidentical transplantation using low-dose thymoglobulin.

Kako S, Gomyo A, Akahoshi Y, Harada N, Kameda K, Ugai T, Wada H, Ishihara Y, Kawamura K, Sakamoto K, Sato M, Terasako-Saito K, Kimura SI, Kikuchi M, Nakasone H, Kanda J, Kanda Y.

Eur J Haematol. 2019 Mar;102(3):256-264. doi: 10.1111/ejh.13204. Epub 2019 Jan 9.

PMID:
30578673
49.

HLA discrepancy between graft and host rather than that graft and first donor impact the second transplant outcome.

Maeda Y, Ugai T, Kondo E, Ikegame K, Murata M, Uchida N, Miyamoto T, Takahashi S, Ohashi K, Nakamae H, Fukuda T, Onizuka M, Eto T, Ota S, Hirokawa M, Ichinohe T, Atsuta Y, Kanda Y, Kanda J; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Haematologica. 2019 May;104(5):1055-1061. doi: 10.3324/haematol.2018.204438. Epub 2018 Dec 6.

50.

Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies.

Minakata D, Fujiwara SI, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Ochi SI, Nagayama T, Mashima K, Umino K, Nakano H, Yamasaki R, Morita K, Kawasaki Y, Sugimoto M, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Ohmori T, Kanda Y.

Int J Hematol. 2019 Feb;109(2):141-146. doi: 10.1007/s12185-018-02567-w. Epub 2018 Dec 8.

PMID:
30536180

Supplemental Content

Support Center